Search for: [Abstract = "This study sought to identify predictive factors for treatment outcomes in stage IV ccRCC patients treated with sunitnib malate. It was a retrospective study, with the sample consisting of twenty\-five patients treated with sunitinib malate for metastatic ccRCC between 2009 and 2013 at the Department of Oncology of the University Hospital in Cracow. I assessed sunitinib malate effects on selected clinical and laboratory indicators by comparing pretreatment values with values observed during treatment. In the second part of the study I assessed the relationship between progression\-free survival times and selected clinical, laboratory, and radiological factors. I found that predictive factors for progression\-free survival times included sunitinib\-malate\-induced hypertension, hand\-foot syndrome \(both assessed after the first treatment cycle\), in\-treatment hypothyroidism, and partial response assessed in an imaging study after the second treatment cycle. A detailed comparison between differences in these parameters in patients who had disease progression at 12.6 months and those who were progression free was carried out. I observed higher prevalence of hypertension, hand\-foot syndrome, hypothyroidism, and myelotoxycity \(lower neutrophil count\) in the group without disease progression at the end of the studied period."]
